GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

eXoZymes EXOZ · USD

Health Care · US listing · 🇺🇸 United States

Compare

4.28

-2.84%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About eXoZymes

From its filings with the US Securities and Exchange Commission

SEC filings

eXoZymes is based in Monrovia, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker EXOZ. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2023, it reported revenue of $70,069.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Nov 2024
Employees
29
Head office
750 ROYAL OAKS DR, MONROVIA, CA, 91016
Incorporated in
NV
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Christopher MarlettChairman of the Board, since 2019
  • Mr. Michael HeltzenChief Executive Officer$381,278
  • Mr. Fouad NawazVice President - Finance$213,090
  • Dr. Tyler KormanVice President - Research$265,949
  • Dr. Paul OpgenorthVice President - Development$261,811
  • Mr. Anthony DiGiandomenicoDirector
  • Mr. Edgardo RayoDirector
  • Dr. Lon BellIndependent Director
  • Dr. James BowieIndependent Director
  • Dr. James LalondeIndependent Director
  • Mr. Lasse GoerlitzVice President - Communications

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Biotechnology sector focus with 29 employees in Health Care industry.
  • SimplePath platform enables enzyme-based biomanufacturing for sustainable solutions.
  • Invizyne Technologies operates in pre-revenue development stage with cell-free technology.

Weaknesses

  • Pre-revenue status limits immediate financial resources for expansion.
  • Limited employee count of 29 may hinder rapid scaling efforts.
  • IPO listing on 13 November 2024 indicates early-stage market entry.

Opportunities

  • Growing demand for natural ingredients in food and beverage sectors.
  • Expansion into pharmaceuticals with therapeutic natural products.
  • Increasing focus on sustainable biomanufacturing processes globally.

Threats

  • Competition from established biotechnology firms in Health Care sector.
  • Regulatory challenges in pharmaceutical and chemical manufacturing.
  • Market volatility affecting early-stage biotech IPOs.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.